IP Library › Granted Patent US 9,028,797
Granted Patent B2
US 9,028,797 · App. 13/581,194 · Granted May 12, 2015

Composite body for antigen or drug delivery

Inventors: Hitoshi Sasaki (Nagasaki, JP); Tomoaki Kurosaki (Nagasaki, JP); Takashi Kitahara (Nagasaki, JP); Hideto To (Nagasaki, JP); Katsuyuki Yui (Nagasaki, JP); Kenji Hirayama (Nagasaki, JP); Kouichi Morita (Nagasaki, JP); Takahiro Mukai (Kobe, JP); Yasuhiro Magata (Hamamatsu, JP); Mikako Ogawa (Hamamatsu, JP); Kohei Sano (North Bethesda, MD)
Assignees: Nagasaki University; Kyusyu University Corporation; National University Corporation Hamamatsu University School of Medicine
A61K49/0002A61K31/711A61K31/713A61K39/0011A61K39/015A61K39/145A61K39/39A61K47/48192A61K47/482A61K51/065A61K2039/5252A61K2039/55555
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,028,797
App. No.
13/581,194
Granted
May 12, 2015
Kind
B2
Abstract

The invention provides an antigen or drug delivery complex containing a complex of an antigen or drug and a cationic molecule, and an anionic molecule encapsulating the same. The antigen or drug delivery complex can be used as a main component of a drug delivery system that delivers various antigens and drugs to a particular cell or organ.

Claims (10)

1. A method of imaging a lymph node in a mammal, comprising

(1) administering to the mammal a complex comprising

(a) a drug complex consisting of a nuclide for imaging, a cationic dendrimer and a chelating agent;

(b) polyethylenimine; and

(c) γ-polyglutamic acid, and

(2) imaging the lymph node in the mammal.

2. The method of claim 1 , wherein the nuclide for imaging is (a) a radioactive nuclide for positron-emission tomography (PET) or compound labeled therewith, (b) a radioactive nuclide for single photon emission computed tomography (SPECT) or compound labeled therewith, (c) contrast agent for nuclear magnetic resonance imaging (MRI) or compound labeled therewith, (d) dye or compound labeled therewith, (e) fluorescent dye or compound labeled therewith, or (f) a compound that is a molecule probe or tracer.

3. The method of claim 1 , wherein the cationic dendrimer is a polyamideamine dendrimer.

4. The method of claim 1 , wherein the chelating agent is p-SCN benzyldiethylenetriamine pentaacetic acid (DTPA).

5. The method of claim 1 , wherein the lymph node is a sentinel lymph node.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2012
From: SASAKI, HITOSHI; KUROSAKI, TOMOAKI; KITAHARA, TAKASHI; TO, HIDETO; YUI, KATSUYUKI; HIRAYAMA, KENJI; MORITA, KOUICHI; MUKAI, TAKAHIRO; MAGATA, YASUHIRO; OGAWA, MIKAKO; SANO, KOHEI
To: NAGASAKI UNIVERSITY; KYUSYU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION; NATIONAL UNIVERSITY CORPORATION HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE
Reel/Frame 029250/0729 →
Priority Claims (1)
JP 2010-043186 · Feb 26, 2010 · national
Continuity (1)
Related Publication 20130052127A1 · Feb 28, 2013